Navigation Links
Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations
Date:5/22/2008

enics Pharmaceuticals, Inc. "We await results within the coming months from a second, ongoing phase 2 study involving the oral formulation of RELISTOR that was announced last July to have positive activity in a phase 1 trial."

RELISTOR Intravenous Formulation

The Progenics-conducted phase 3 study of an intravenous formulation of RELISTOR for patients with post-operative ileus (POI) did not meet the primary or secondary end points, confirming the earlier findings of the Wyeth phase 3 intravenous POI study announced on March 12, 2008. Progenics and Wyeth will now study the results of both phase 3 intravenous POI studies to determine whether and how to continue development of this formulation of RELISTOR and this indication.

RELISTOR Franchise

"We are committed to continuing to develop the RELISTOR franchise to help address the unmet medical needs of patients suffering from the gastrointestinal side effects of opioids. Following the results from a second phase 2 clinical trial of another oral formulation, Wyeth and Progenics will further define the continued development plan for oral RELISTOR," says Gary L. Stiles, M.D., Executive Vice President, Chief Medical Officer, Wyeth Pharmaceuticals.

About RELISTOR and Opioids

RELISTOR is a peripherally acting mu-opioid receptor antagonist that counteracts the constipating effects of opioid pain medications in the gastrointestinal tract without affecting their ability to relieve pain.

Opioids provide pain relief by specifically interacting with mu-opioid receptors within the central nervous system (CNS) -- the brain and spinal cord. However, opioids also interact with mu-opioid receptors found outside the CNS, such as those within the gastrointestinal tract, resulting in constipation that can be debilitating. RELISTOR selectively displaces opioids from the mu-opioid receptors outside the CNS, including those located in the gastrointestinal tract, thereby decreasing their constipa
'/>"/>

SOURCE Wyeth Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
2. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
3. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
4. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
5. FDA Accepts Wyeths Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
6. Wyeths TORISEL Receives European Commission Approval for the Treatment of Advanced Kidney Cancer
7. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
8. Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014  BC Technical, the ... acquired Polaris Medical Imaging, a leader in sales, service ... strategic acquisition allows BC Technical to continue to expand ... within MR and CT modalities. "We ... said Mark Alvarez , president and CEO of ...
(Date:8/29/2014)... DENVER , Aug. 29, 2014 Does your ... date, nearly 800 doctors have recommended marijuana to the over ... Amendment 20. But the majority of the other roughly 20,300+ ... still know very little about it – even though a ... adults say they have tried it. ...
(Date:8/29/2014)... , Aug. 29, 2014 Diseases largely eradicated ... generation ago are returning. Measles was declared eliminated in ... 2014 as of August 15—the highest incidence in 20 ... health department declared whooping cough a problem of ... getting sick and dying from these preventable diseases—in part ...
Breaking Medicine Technology:BC Technical Acquires Polaris Medical Imaging 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 3Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 4Vaccines at the Crossroads: Outbreaks On the Rise Across America 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 3
... 2007 /PRNewswire-FirstCall/ -- On Wednesday,July 11, 2007, ... European Time members of Cell Therapeutics, Inc.'s ... to discuss today's,announcement of the interim results ... to CPOP-R, in which pixantrone is substituted ...
... in a physicians office practice, can be instrumental ... ailments; UTIs, diabetes, several cancers, metabolic disorders, cardiovascular ... for urinalysis tests is well in excess of ... For such a fundamental, extensive and economically significant ...
Cached Medicine Technology:Cell Therapeutics, Inc. Management to Discuss Today's Announcement,of Interim Pixantrone Study Results 2Urinalysis Analyzers: Large Capabilities in Every Size Device 2Urinalysis Analyzers: Large Capabilities in Every Size Device 3
(Date:8/29/2014)... (PRWEB) August 29, 2014 Honey Gifts, ... the company will now be selling purse-sized adult toys ... a way that they can be carried in a ... portable, the purse-sized range at Honey Gifts is also ... battery life and rechargeable batteries are common characteristics of ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 The ... sparse revenue growth over the five years to ... recession, consumers had less disposable income and, consequently, ... and visited restaurants less frequently. As a result, ... declined, hindering revenue growth. “After 2010, levels of ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Evolutions Medical ... Barbara in the Santa Barbara News-Press Readers’ Choice 2014 ... the Readers’ Choice poll as Best Medical Spa. The ... reads the following about Evolutions Medical Spa recognition: , ... it is recognized as a top-notch, cutting-edge medical spa ...
(Date:8/29/2014)... 29, 2014 September yoga month was ... of yoga and its health benefits. To support this ... join their "Yoga Month Challenge" , This 4 week ... new and experienced yogis practice yoga regularly from their ... Month Challenge ' is suitable for all levels, and ...
(Date:8/29/2014)... Ohio (PRWEB) August 29, 2014 ... president of operations & business development. , Rees has ... vice president of business development. , A wholly owned ... Senior Independence provides older adults with options, including personalized ... in-home care (e.g., meal preparation) and therapeutic adult day ...
Breaking Medicine News(10 mins):Health News:Honey Gifts Now Provides Purse Sized Adult Toys in Vancouver 2Health News:Fruit and Vegetable Wholesaling in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Fruit and Vegetable Wholesaling in Canada Industry Market Research Report Now Available from IBISWorld 3Health News:Evolutions Named Best Medical Spa in Santa Barbara by Santa Barbara News Press 2Health News:Evolutions Named Best Medical Spa in Santa Barbara by Santa Barbara News Press 3Health News:Ekhart Yoga Launches the Yoga Month Challenge 2Health News:Senior Independence Promotes Rees to Vice President of Operations & Business Development 2
... Operating Cash Flow of $173 Million, and Generates $98 ... to Reflect Year-to-Date Sales Results, Maintains Bottom-Line GuidanceAUSTIN, Texas, ... WFMI ) today reported results for the 12-week ... the quarter were $1.9 billion, in line with the ...
... clinical trial led by Dr. Katherine Borden, at the ... the Universit de Montral, has shown that a common ... of cancer patients. Published in the journal Blood ... the activities of the eIF4E gene in patients. This ...
... American Pathologists today joined a lawsuit against the U.S. Patent and ... for the genes known as BRCA1 and BRCA2, which are indicators ... ... Washington, D.C. (Vocus) May 13, 2009 -- The College of ...
... the findings of a landmark drug comparison study published in ... other medications for high blood pressure. A scientific team including ... Houston reports the findings in the May 11 issue of ... in three adults in the United States has high blood ...
... be the newest "Biggest Loser" but she is a real ... is about simple, everyday choices that can help you be ... the glass and is one of the simplest things you ... and athletes to don a ,stache for the National Milk ...
... combination medication approved with the extended-release form of ... Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, ... announced that the U.S. Food and Drug Administration ... medication ACTO plus met(R) (pioglitazone HCl and ...
Cached Medicine News:Health News:Whole Foods Market Reports Second Quarter 2009 Results 2Health News:Whole Foods Market Reports Second Quarter 2009 Results 3Health News:Whole Foods Market Reports Second Quarter 2009 Results 4Health News:Whole Foods Market Reports Second Quarter 2009 Results 5Health News:Whole Foods Market Reports Second Quarter 2009 Results 6Health News:Whole Foods Market Reports Second Quarter 2009 Results 7Health News:Whole Foods Market Reports Second Quarter 2009 Results 8Health News:Whole Foods Market Reports Second Quarter 2009 Results 9Health News:Whole Foods Market Reports Second Quarter 2009 Results 10Health News:Whole Foods Market Reports Second Quarter 2009 Results 11Health News:Whole Foods Market Reports Second Quarter 2009 Results 12Health News:Whole Foods Market Reports Second Quarter 2009 Results 13Health News:Whole Foods Market Reports Second Quarter 2009 Results 14Health News:Whole Foods Market Reports Second Quarter 2009 Results 15Health News:Whole Foods Market Reports Second Quarter 2009 Results 16Health News:Whole Foods Market Reports Second Quarter 2009 Results 17Health News:Whole Foods Market Reports Second Quarter 2009 Results 18Health News:Whole Foods Market Reports Second Quarter 2009 Results 19Health News:Whole Foods Market Reports Second Quarter 2009 Results 20Health News:Whole Foods Market Reports Second Quarter 2009 Results 21Health News:Novel therapy may prove effective in treatment of 30 percent of cancers 2Health News:CAP Joins Landmark Lawsuit Challenging Legality of Myriad Genetics Gene Patents 2Health News:New research confirms milestone study on blood pressure meds 2Health News:New research confirms milestone study on blood pressure meds 3Health News:FDA Approves ACTOplus met(R) XR (pioglitazone HCl and metformin HCl extended-release) Tablets for the Treatment of Type 2 Diabetes 2Health News:FDA Approves ACTOplus met(R) XR (pioglitazone HCl and metformin HCl extended-release) Tablets for the Treatment of Type 2 Diabetes 3Health News:FDA Approves ACTOplus met(R) XR (pioglitazone HCl and metformin HCl extended-release) Tablets for the Treatment of Type 2 Diabetes 4
Clinical micro clamps by Acland. Matte finish. It provides impressive security in use, both against slippage and against leakage due to controlled closing force and working grip surface....
Micro emulsifying needles, 18G....
Micro 2000, micro scissors micro 2000 supercut....
Yasargil clip applying forceps Mini. Stainless steel jaw....
Medicine Products: